Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140009/S140

Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger

ABBOTT MEDICAL · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP140009/S140

What did the FDA decide?

The FDA record for P140009/S140, a 30-Day Notice categorized as a process change involving a manufacturer, sterilizer, packager or supplier, describes an approval to use an alternate third-tier supplier for FR-4 material. That material goes into manufacturing the printed circuit boards for the Chargers of the Eterna SCS IPG and Liberta RC DBS IPG. The applicant listed is Abbott Medical, the device category is an implanted electrical stimulator for parkinsonian tremor, the specialty is Neurology, and the product code is MHY.

The identifier P140009 links the notice to the original PMA and frames it as a supplement, not a new approval of the whole system. The supplied statement does not identify the supplier, describe qualification testing, or present data on safety or effectiveness; its reported purpose is a supplier change, which is not itself independent proof of either. The decision date field reads 2026-09-11.

FDA approval order statement

approval to utilize an alternate third-tier supplier for the FR-4 material, which is used in the manufacture of the printed circuit boards for the Chargers of the Eterna SCS IPG and Liberta RC DBS IPG
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Sep 11, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140009/S140
Regulatory pathway
PMA supplement
Product code
MHY
Decision code
OK30
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.

Product code
MHY
FDA device class
3

For the original device and its historical approval scope, see PMA P140009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140009 · Original PMA

    BRIO NEUROSTIMULATION SYSTEM

  2. P140009/S140 received

    Application receipt date recorded by FDA.

  3. P140009/S140 · FDA decision

    30-Day Notice

  4. P140009/S143 · Related supplement

    Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generator

  5. P140009/S141 · Related supplement

    Deep Brain Stimulation (DBS) EPG

  6. P140009/S142 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger

  7. P140009/S144 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG)

Timeline entries are records held by MedtechLedger for P140009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140009

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalJun 12, 2015FDA
Infinity DBS IPGP140009/S139
ABBOTT MEDICALPMA supplementSep 23, 2026FDA
ABBOTT MEDICALPMA supplementOct 27, 2026FDA
ABBOTT MEDICALPMA supplementOct 28, 2026FDA
ABBOTT MEDICALPMA supplementOct 30, 2026FDA
ABBOTT MEDICALPMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code MHY

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6901 Prestion Rd., Plano, TX, 75024

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records